4 completed. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 1 | Completed 1 |
Follow CP protocol: new trials by email Literature Review of CP protocol trials Research Report on CP protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 Niraparib, TSR-042, Carboplatin-Paclitaxel - Neoplasms, Metastatic Cancer | Phase 1 | Completed | Tesaro, Inc. | 60 | 2017-10-12 | 2025-11-25 |
| Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors paclitaxel + carboplatin, carboplatin + etoposide, gemcitabine + carboplatin - Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck | Phase 1 | Completed | AstraZeneca | 32 | 2016-04-28 | 2020-08-20 |
| Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer Carboplatin/paclitaxel - Advanced Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Completed | Cairo University | 49 | 2015-01-01 | 2023-07-27 |
| Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel KU-0059436 (AZD2281)(PARP inhibitor), Carboplatin, Paclitaxel - Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer | Phase 1 | Completed | AstraZeneca | 189 | 2007-06-22 | 2025-04-11 |
Neoplasm Metastasis (2) · Anemia (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Pancreatic Ductal (1) · Esophageal Squamous Cell Carcinoma (1) · Fallopian Tube Neoplasms (1) · Neoplasms (1) · Neutropenia (1) · Ovarian Neoplasms (1) · Peritoneal Neoplasms (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Thrombocytopenia (1) · Triple Negative Breast Neoplasms (1)
AstraZeneca (2) · Cairo University (1) · Tesaro, Inc. (1)
Belgium (1) · Egypt (1) · Japan (1) · Netherlands (1) · South Korea (1) · United Kingdom (1) · United States (1)
Dr Johann de Bono, MD (1) · Jane Robertson, BSc, MBCHB, MD (1) · Prof Jan HM Schellens (1)